Literature DB >> 12632492

Studies on microsatellite instability in p16 gene and expression of hMSH2 mRNA in human gastric cancer tissues.

Qin-Xian Zhang1, Yi Ding, Xiao-Ping Le, Peng Du.   

Abstract

AIM: To detect the loss of heterozygosity (LOH) frequency of microsatellite sites D9s171, D9s1604 of p16 gene and expression of hMSH2 mRNA in various differentiated types of gastric cancer, adjacent cancer tissues and normal gastric mucosa.
METHODS: LOH was detected by polymerase chain reaction (PCR)-denaturing polyacrylamide gel electrophoresis-silver staining. The expression of hMSH2 mRNA was examined with in situ hybridization.
RESULTS: The frequency rate of LOH was significantly higher in gastric cancers than that in adjacent cancer tissues (P=0.032). No significant difference was noted among various differentiated types and various clinical stages of gastric cancers. The significantly reduced expression of hMSH2 mRNA positive signal cells exhibited in gastric cancers, in comparison with that in the adjacent cancer tissues and normal gastric mucosa, respectively (P=0.001). No significant difference was noted among various clinical stages of gastric cancers (P>0.05). The difference of positive signal cells in poorly differentiated cancers and those in well and moderately differentiated cancers were significant (P<0.001).
CONCLUSION: The frequencies of LOH in two microsatellite sites, D9s171 and D9s1604, in p16 genome were associated with development of gastric cancer and no significant correlation was demonstrated between the LOH frequency and the cell differentiated types of tumor cells or clinical stages. There was a positive relationship between the expression of hMSH2 mRNA and the differentiated types of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12632492      PMCID: PMC4621556          DOI: 10.3748/wjg.v9.i3.437

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

1.  Expression, deletion [was deleton] and mutation of p16 gene in human gastric cancer.

Authors:  X S He; Q Su; Z C Chen; X T He; Z F Long; H Ling; L R Zhang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  Accumulated frameshift mutations at coding nucleotide repeats during the progression of gastric carcinoma with microsatellite instability.

Authors:  J J Kim; M J Baek; L Kim; N G Kim; Y C Lee; S Y Song; S H Noh; H Kim
Journal:  Lab Invest       Date:  1999-09       Impact factor: 5.662

3.  Microsatellite instability is associated with genetic alteration but not with low levels of expression of the human mismatch repair proteins hMSH2 and hMLH1.

Authors:  K H Shin; J G Park
Journal:  Eur J Cancer       Date:  2000-05       Impact factor: 9.162

4.  Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas.

Authors:  N E Spanakis; V Gorgoulis; G Mariatos; P Zacharatos; A Kotsinas; G Garinis; R Trigidou; A Karameris; H Tsimara-Papastamatiou; M Kouloukousa; E N Manolis; C Kittas
Journal:  Anticancer Res       Date:  1999 May-Jun       Impact factor: 2.480

5.  Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability.

Authors:  A S Fleisher; M Esteller; S Wang; G Tamura; H Suzuki; J Yin; T T Zou; J M Abraham; D Kong; K N Smolinski; Y Q Shi; M G Rhyu; S M Powell; S P James; K T Wilson; J G Herman; S J Meltzer
Journal:  Cancer Res       Date:  1999-03-01       Impact factor: 12.701

6.  Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype.

Authors:  H Yamamoto; H Sawai; M Perucho
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

7.  Expression of the mismatch repair protein hMSH2 in carcinoma in situ and invasive cancer of the breast.

Authors:  N Bock; H Meden; M Regenbrecht; B Jünemann; J Wangerin; D Marx
Journal:  Anticancer Res       Date:  2000 Jan-Feb       Impact factor: 2.480

8.  Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer.

Authors:  H J Han; A Yanagisawa; Y Kato; J G Park; Y Nakamura
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

9.  Prognostic value and clinicopathological profile of microsatellite instability in gastric cancer.

Authors:  H C Wirtz; W Müller; T Noguchi; M Scheven; J Rüschoff; G Hommel; H E Gabbert
Journal:  Clin Cancer Res       Date:  1998-07       Impact factor: 12.531

10.  CDKN2A gene inactivation in epithelial sporadic ovarian cancer.

Authors:  D Niederacher; H Y Yan; H X An; H G Bender; M W Beckmann
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

View more
  5 in total

1.  Correlation between gastric carcinoma and ZAC gene-associated microsatellite instability and loss of heterozygosity.

Authors:  Xiao-Yan Zhu; Ji-Yao Yang; Ying He; Guo-Hong Liu; Yun Sun; Yi Ding
Journal:  Oncol Lett       Date:  2017-06-15       Impact factor: 2.967

Review 2.  Primary adenocarcinomas of lower esophagus, esophagogastric junction and gastric cardia: in special reference to China.

Authors:  Li-Dong Wang; Shu Zheng; Zuo-Yu Zheng; Alan G Casson
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

3.  Microsatellite Alterations and Protein Expression of 5 Major Tumor Suppressor Genes in Gastric Adenocarcinomas.

Authors:  Won Hyuk Choi; Sookhyun Lee; Sungjin Cho
Journal:  Transl Oncol       Date:  2017-11-21       Impact factor: 4.243

4.  Analysis of the Expression and Prognostic Value of MSH2 in Pan-Cancer Based on Bioinformatics.

Authors:  Wenli Qiu; Ke Ding; Lusheng Liao; Yongchang Ling; Xiaoqiong Luo; Junli Wang
Journal:  Biomed Res Int       Date:  2021-11-23       Impact factor: 3.411

5.  A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer.

Authors:  Heidi Schwarzenbach; Volkmar Müller; Cord Beeger; Miriam Gottberg; Nicole Stahmann; Klaus Pantel
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.